For Oncor, the luxury of R&D still exists

While many biotech companies are thinking about cutting their R&D budgets to conserve scarce resources, those with strong cash positions have the luxury of expanding their pipelines and building for the future.

Driven by the outpouring of gene discoveries from the human genome project, Oncor Inc. decided to increase its 1993 R&D budget by $2.5 million over plan, from $6.5 million to $9 million, according to Chairman and CEO Stephen Turner. The company develops and markets gene-based test systems for the detection and management of cancer and other genetic diseases...